卡西利韦单抗和伊马单抗（CAS+IMD）在COVID-19儿科门诊患者中的安全性和药代动力学。

IF 2.5 4区医学 Q3 INFECTIOUS DISEASES

Journal of the Pediatric Infectious Diseases Society Pub Date : 2024-10-01 DOI:10.1093/jpids/piae105

Thomas D Norton, Mazhar Thakur, Samit Ganguly, Shazia Ali, Jesse Chao, Alpana Waldron, Jing Xiao, Kenneth C Turner, John D Davis, Susan C Irvin, Cynthia Pan, Dominique Atmodjo, Andrea T Hooper, Jennifer D Hamilton, Mohamed Hussein, Danise Subramaniam, Lilia Roque-Guerrero, Anita Kohli, Eleftherios Mylonakis, Gregory P Geba, Edward Cox, Ned Braunstein, Paula Dakin, Bari Kowal, Rafia Bhore, A Thomas DiCioccio, Diana Hughes, Gary A Herman

{"title":"卡西利韦单抗和伊马单抗（CAS+IMD）在COVID-19儿科门诊患者中的安全性和药代动力学。","authors":"Thomas D Norton, Mazhar Thakur, Samit Ganguly, Shazia Ali, Jesse Chao, Alpana Waldron, Jing Xiao, Kenneth C Turner, John D Davis, Susan C Irvin, Cynthia Pan, Dominique Atmodjo, Andrea T Hooper, Jennifer D Hamilton, Mohamed Hussein, Danise Subramaniam, Lilia Roque-Guerrero, Anita Kohli, Eleftherios Mylonakis, Gregory P Geba, Edward Cox, Ned Braunstein, Paula Dakin, Bari Kowal, Rafia Bhore, A Thomas DiCioccio, Diana Hughes, Gary A Herman","doi":"10.1093/jpids/piae105","DOIUrl":null,"url":null,"abstract":"The safety of casirivimab+imdevimab (CAS+IMD) (anti-SARS-CoV-2 monoclonal antibodies [mAbs]) in pediatric outpatients with COVID-19 was evaluated in a randomized, phase 1/2/3 trial. Consistent with adults, CAS+IMD was generally well tolerated with low drug-induced immunogenicity rates. The findings support development of next-generation anti-SARS-CoV-2 mAbs for at-risk pediatric patients.","PeriodicalId":17374,"journal":{"name":"Journal of the Pediatric Infectious Diseases Society","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS+IMD) in Pediatric Outpatients With COVID-19.\",\"authors\":\"Thomas D Norton, Mazhar Thakur, Samit Ganguly, Shazia Ali, Jesse Chao, Alpana Waldron, Jing Xiao, Kenneth C Turner, John D Davis, Susan C Irvin, Cynthia Pan, Dominique Atmodjo, Andrea T Hooper, Jennifer D Hamilton, Mohamed Hussein, Danise Subramaniam, Lilia Roque-Guerrero, Anita Kohli, Eleftherios Mylonakis, Gregory P Geba, Edward Cox, Ned Braunstein, Paula Dakin, Bari Kowal, Rafia Bhore, A Thomas DiCioccio, Diana Hughes, Gary A Herman\",\"doi\":\"10.1093/jpids/piae105\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The safety of casirivimab+imdevimab (CAS+IMD) (anti-SARS-CoV-2 monoclonal antibodies [mAbs]) in pediatric outpatients with COVID-19 was evaluated in a randomized, phase 1/2/3 trial. Consistent with adults, CAS+IMD was generally well tolerated with low drug-induced immunogenicity rates. The findings support development of next-generation anti-SARS-CoV-2 mAbs for at-risk pediatric patients.\",\"PeriodicalId\":17374,\"journal\":{\"name\":\"Journal of the Pediatric Infectious Diseases Society\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the Pediatric Infectious Diseases Society\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/jpids/piae105\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Pediatric Infectious Diseases Society","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jpids/piae105","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

一项1/2/3期随机试验评估了卡西利韦单抗+伊美替尼（Casirivimab+imdevimab，CAS+IMD）（抗SARS-CoV-2单克隆抗体[mAbs]）在COVID-19儿科门诊患者中的安全性。与成人相同，CAS+IMD 的耐受性普遍良好，药物诱导的免疫原性较低。研究结果支持为高危儿科患者开发新一代抗 SARS-CoV-2 mAbs。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS+IMD) in Pediatric Outpatients With COVID-19.

The safety of casirivimab+imdevimab (CAS+IMD) (anti-SARS-CoV-2 monoclonal antibodies [mAbs]) in pediatric outpatients with COVID-19 was evaluated in a randomized, phase 1/2/3 trial. Consistent with adults, CAS+IMD was generally well tolerated with low drug-induced immunogenicity rates. The findings support development of next-generation anti-SARS-CoV-2 mAbs for at-risk pediatric patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of the Pediatric Infectious Diseases Society Medicine-Pediatrics, Perinatology and Child Health

CiteScore

6.70

自引率

0.00%

发文量

179

期刊介绍： The Journal of the Pediatric Infectious Diseases Society (JPIDS), the official journal of the Pediatric Infectious Diseases Society, is dedicated to perinatal, childhood, and adolescent infectious diseases. The journal is a high-quality source of original research articles, clinical trial reports, guidelines, and topical reviews, with particular attention to the interests and needs of the global pediatric infectious diseases communities.